Importantly, PIK3CA genetic testing and the use of Alpelisib for HR + /HER2- breast cancer patients with PIK3CA mutation have been included in the National Comprehensive Cancer Network (NCCN) breast cancer clinical practice guidelines. The gene discussed is PIK3CA; the disease is breast carcinoma.